Cargando…

Circulating levels of PCSK9, ANGPTL3 and Lp(a) in stage III breast cancers

BACKGROUND / SYNOPSIS: Cholesterol and lipids play an important role in sustaining tumor growth and metastasis in a large variety of cancers. ANGPTL3 and PCSK9 modify circulating cholesterol levels, thus availability of lipids to peripheral cells. Little is known on the role, if any, of circulating...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wong Chong, Emilie, Joncas, France-Hélène, Seidah, Nabil G., Calon, Frédéric, Diorio, Caroline, Gangloff, Anne
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9535963/ https://www.ncbi.nlm.nih.gov/pubmed/36203122 http://dx.doi.org/10.1186/s12885-022-10120-6

Ejemplares similares

The PCSK9 revolution and the potential of PCSK9-based therapies to reduce LDL-cholesterol
por: Seidah, Nabil G.
Publicado: (2017)

The Multifaceted Biology of PCSK9
por: Seidah, Nabil G, et al.
Publicado: (2021)

Expanding Biology of PCSK9: Roles in Atherosclerosis and Beyond
por: Seidah, Nabil G., et al.
Publicado: (2022)

Evidence from a Randomized Trial That Simvastatin, but Not Ezetimibe, Upregulates Circulating PCSK9 Levels
por: Berthold, Heiner K., et al.
Publicado: (2013)

The PCSK9 discovery, an inactive protease with varied functions in hypercholesterolemia, viral infections, and cancer
por: Seidah, Nabil G.
Publicado: (2021)

PCSK9 Prosegment Chimera as Novel Inhibitors of LDLR Degradation
por: Luna Saavedra, Yascara Grisel, et al.
Publicado: (2013)

PCSK9 in Liver Cancers at the Crossroads between Lipid Metabolism and Immunity
por: Alannan, Malak, et al.
Publicado: (2022)

Metabolic effects of PCSK9 inhibition with Evolocumab in subjects with elevated Lp(a)
por: Zhang, Xiang, et al.
Publicado: (2020)

Monoclonal Antibodies in the Management of Familial Hypercholesterolemia: Focus on PCSK9 and ANGPTL3 Inhibitors
por: Pirillo, Angela, et al.
Publicado: (2021)

SUN-580 PCSK9 and Lp(a): Association Between PCSK9 Level and Larger Apo(a) Isoform Size in African-Americans and Caucasians
por: Byambaa, Enkhmaa, et al.
Publicado: (2020)

The Concentration of PCSK9-Lp(a) Complexes and the Level of Blood Monocytes in Males with Coronary Atherosclerosis
por: Filatova, Anastasiia Yu., et al.
Publicado: (2023)

PCSK9 Contributes to the Cholesterol, Glucose, and Insulin2 Homeostasis in Seminiferous Tubules and Maintenance of Immunotolerance in Testis
por: Pelletier, R.-Marc, et al.
Publicado: (2022)

Post-transcriptional Regulation of PCSK9 by miR-191, miR-222, and miR-224
por: Naeli, Parisa, et al.
Publicado: (2017)

PCSK9 in African Americans and Caucasians in Relation to Lp(a) Level, Apo(a) Size and Heritability
por: Enkhmaa, Byambaa, et al.
Publicado: (2020)

Circulating PCSK9 Linked to Dyslipidemia in Lebanese Schoolchildren
por: Azar, Yara, et al.
Publicado: (2022)

Decreased PCSK9 expression in human hepatocellular carcinoma
por: Bhat, Mamatha, et al.
Publicado: (2015)

Circulating Angptl3 and Angptl8 Are Increased in Patients with Hypothyroidism
por: Yang, Longyan, et al.
Publicado: (2019)

PCSK9 facilitates melanoma pathogenesis via a network regulating tumor immunity
por: Gu, Yan, et al.
Publicado: (2023)

Dengue virus induces PCSK9 expression to alter antiviral responses and disease outcomes
por: Gan, Esther Shuyi, et al.
Publicado: (2020)

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Can Mediate Degradation of the Low Density Lipoprotein Receptor-Related Protein 1 (LRP-1)
por: Canuel, Maryssa, et al.
Publicado: (2013)

PCSK9 is not secreted from mature differentiated intestinal cells
por: Moreau, François, et al.
Publicado: (2021)

ANGPTL4 sensitizes lipoprotein lipase to PCSK3 cleavage by catalyzing its unfolding
por: Lund Winther, Anne-Marie, et al.
Publicado: (2021)

Pcsk5 is required in the early cranio-cardiac mesoderm for heart development
por: Szumska, Dorota, et al.
Publicado: (2017)

Lipid Lowering Therapy and Circulating PCSK9 Concentration
por: Nozue, Tsuyoshi
Publicado: (2017)

Annexin A2 Is a Natural Extrahepatic Inhibitor of the PCSK9-Induced LDL Receptor Degradation
por: Seidah, Nabil G., et al.
Publicado: (2012)

Lomitapide does not alter PCSK9 and Lp(a) levels in homozygous familial hypercholesterolemia patients: Analysis on cytokines and lipid profile
por: Lupo, Maria Giovanna, et al.
Publicado: (2021)

A Locked Nucleic Acid Antisense Oligonucleotide (LNA) Silences PCSK9 and Enhances LDLR Expression In Vitro and In Vivo
por: Gupta, Nidhi, et al.
Publicado: (2010)

PCSK9 regulates the NODAL signaling pathway and cellular proliferation in hiPSCs
por: Roudaut, Meryl, et al.
Publicado: (2021)

Circulating ANGPTL3 and ANGPTL4 levels predict coronary artery atherosclerosis severity
por: Sun, Ting, et al.
Publicado: (2021)

Asialoglycoprotein receptor 1 is a novel PCSK9-independent ligand of liver LDLR cleaved by furin
por: Susan-Resiga, Delia, et al.
Publicado: (2021)

Mutational Spectrum of LDLR and PCSK9 Genes Identified in Iranian Patients With Premature Coronary Artery Disease and Familial Hypercholesterolemia
por: Moradi, Arman, et al.
Publicado: (2021)

PCSK9 and LDLR degradation: regulatory mechanisms in circulation and in cells
por: Lagace, Thomas A.
Publicado: (2014)

The predictive utility of circulating PCSK9 levels on diabetes mellitus
por: Peng, Jia, et al.
Publicado: (2021)

Sex difference in circulating PCSK9 and its clinical implications
por: Jia, Fang, et al.
Publicado: (2022)

Variable Changes of Circulating ANGPTL3 and ANGPTL4 in Different Obese Phenotypes: Relationship with Vasodilator Dysfunction
por: Schinzari, Francesca, et al.
Publicado: (2021)

Circulating PCSK9 and Risk of Myocardial Infarction: The HUNT Study in Norway
por: Laugsand, Lars E., et al.
Publicado: (2016)

Pcsk9 knockout exacerbates diet-induced non-alcoholic steatohepatitis, fibrosis and liver injury in mice
por: Lebeau, Paul F., et al.
Publicado: (2019)

Circulating PCSK9 Level and Risk of Cardiovascular Events and Death in Hemodialysis Patients
por: Hwang, Hyeon Seok, et al.
Publicado: (2020)

Circulating Mature PCSK9 Level Predicts Diminished Response to Statin Therapy
por: Kuyama, Naoto, et al.
Publicado: (2021)

Relationship between Circulating PCSK9 and Markers of Subclinical Atherosclerosis—The IMPROVE Study
por: Coggi, Daniela, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_5vn85vgc7gi69pehisu482lfi5